Comparison of adjuvant chemotherapy and radiation in patients with intermediate risk factors after radical surgery in FIGO stage IB-IIA cervical cancer
Comparison of adjuvant chemotherapy and radiation in patients with intermediate risk factors after radical surgery in FIGO stage IB-IIA cervical cancer
复制标题
DOI：
10.1111/j.1525-1438.2007.01136.x
复制
发表时间：
2008-09-01
影响因子：
4.8
通讯作者：
Ha, S. -Y.
中科院分区：
文献类型：
--
作者：
Lee, K. -B.;Lee, J. -M.;Ha, S. -Y.
本研究的目的是比较化疗或放疗作为辅助治疗的FIGO阶段IB-IIA宫颈癌和手术证实的中间风险因素的患者的结果。数据收集自宫颈癌FIGO IB-IIA期患者，这些患者在根治性子宫切除术伴盆腔淋巴结清扫术（RHLND，病例）后接受辅助化疗或在RHLND后接受辅助放疗（对照）。研究组包括38例病例和42例对照。对合并有中间风险因素的患者给予辅助治疗，这些风险因素包括深基质侵犯（> 50%）、淋巴管间隙侵犯、肿瘤大小大（3 - 6 cm）或阴道切除边缘近（<1 cm）。病例与对照组的比较显示，包括中位年龄在内的变量研究没有显着差异（P = 0.18），分期分布（P = 0.30），组织学亚型（P = 0.93），病理肿瘤大小（P = 0.46）、间质浸润深度（P = 0.29）、淋巴管间隙浸润（P = 0.50）和阴道切缘较近（P = 0.62）。无病生存率差异无统计学意义（P = 0.68）。然而，由于研究期结束时可用的事件数量有限，因此总生存期分析不完整。本研究的结果表明，辅助化疗的患者FIGO阶段IB-IIA宫颈癌和手术证实的中间风险因素可能是有效的。
The aim of this study was to compare the outcome of chemotherapy or radiation as adjuvant therapy for patients with FIGO stage IB-IIA cervical cancer and surgically confirmed intermediate risk factors. Data were collected from patients with uterine cervical cancer FIGO stage IB-IIA who had adjuvant chemotherapy following radical hysterectomy with pelvic lymph node dissection (RHLND, cases) or adjuvant radiotherapy following RHLND (controls). The study groups consisted of 38 cases and 42 controls. Adjuvant treatment was given to the patients with a combination of intermediate risk factors including deep stromal invasion (> 50%), lymphvascular space invasion, large tumor size (3-6 cm), or close vaginal resection margin (< 1 cm). Comparison of the cases with the controls revealed no significant differences in variables studied including median age (P = 0.18), stage distribution (P = 0.30), histologic subtype (P = 0.93), pathologic tumor size (P = 0.46), depth of the stromal invasion (P = 0.29), lymphvascular space invasion (P = 0.50), and close vaginal resection margin (P = 0.62). The difference in disease-free survival rates was not significant (P = 0.68). However, the overall survival analysis was incomplete due to the limited number of events available at the end of the study period. The findings of this study suggest that adjuvant chemotherapy in patients with FIGO stage IB-IIA uterine cervical cancer and surgically confirmed intermediate risk factors may be effective.